Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal.

Sujan T ReddyT C CosseySean I SavitzJames C Grotta

Published in: Current neurology and neuroscience reports (2018)

Idarucizumab is a reversal agent approved for dabigatran, and two more reversal agents, andexanet alfa and aripazine, are currently in development for NOACs. In this article, we review currently available NOACs, their laboratory monitoring, and reversal agents.

Keyphrases

oral anticoagulants
atrial fibrillation